Terms: = Uterine cancer AND CYLD, CYLD1, 1540, ENSG00000083799, USPL2, KIAA0849, CYLDI, CDMT, HSPC057, FLJ31664, FLJ20180, EAC AND Prognosis
24 results:
1. Endometrial cytological findings for a mesonephric-like endometrial adenocarcinoma: A case report.
Omine H; Ishida K; Sasaki N; Kato H; Nagai T; Ishikawa M; Takaoka M; Noda S; Matsuda H; Mitsuhashi A
Diagn Cytopathol; 2024 Jun; 52(6):E129-E133. PubMed ID: 38454318
[TBL] [Abstract] [Full Text] [Related]
2. Invasive stratified mucin-producing carcinoma (ISMC) of the cervix: a clinicopathological and molecular analysis of 59 cases with special emphasis on histogenesis and potential therapeutic targets.
Yao Y; Wang Y; Ye L; Lu B; Lu W
Histopathology; 2024 Jan; 84(2):315-324. PubMed ID: 37735961
[TBL] [Abstract] [Full Text] [Related]
3. Using Silva pattern system to predict prognosis and plan treatment of invasive endocervical adenocarcinoma: a single-center retrospective analysis.
Li X; Pang S; Shen Y; Qu P
BMC Womens Health; 2022 Dec; 22(1):488. PubMed ID: 36460984
[TBL] [Abstract] [Full Text] [Related]
4. Silva cumulative score and its relationship with prognosis in Endocervical adenocarcinoma.
Li Y; Jia M; Cao L; Yu J; Gao H; Sun PL
BMC Cancer; 2022 Nov; 22(1):1172. PubMed ID: 36376880
[TBL] [Abstract] [Full Text] [Related]
5. cyld expression in endometrial carcinoma and correlation with clinicohistopathological parameters.
Papadatou V; Tologkos S; Tsolou A; Deftereou TE; Liberis A; Trypsianis G; Alexiadis T; Georgiadi K; Alexiadi CA; Nikolaidou C; Lambropoulou M
Taiwan J Obstet Gynecol; 2022 Jul; 61(4):596-600. PubMed ID: 35779906
[TBL] [Abstract] [Full Text] [Related]
6. Clinical characteristic and prognostic factors in high-grade endometrial neuroendocrine carcinoma.
Zhang Z; Wang J; Wu X; Liu Y; Xi X
J Obstet Gynaecol Res; 2022 Aug; 48(8):2180-2188. PubMed ID: 35778826
[TBL] [Abstract] [Full Text] [Related]
7. Independent validation of distinct clinicopathological features and prognosis among usual-type, mucinous-type and gastric-type endocervical adenocarcinoma categorised by new WHO classification (2020).
Shi H; Shao Y; Zhang H; Ye L; Xu E; Lu B
Pathology; 2022 Aug; 54(5):555-562. PubMed ID: 35346505
[TBL] [Abstract] [Full Text] [Related]
8. Overview of adjuvant radiotherapy on survival, failure pattern and toxicity in stage I to II endometrial carcinoma: a long-term multi-institutional analysis in China.
Wang W; Wang T; Liu Z; He J; Sun X; Zhong W; Zhao F; Li X; Li S; Zhu H; Ma Z; Hu K; Zhang F; Hou X; Wei L; Zou L
BMC Cancer; 2022 Mar; 22(1):266. PubMed ID: 35287626
[TBL] [Abstract] [Full Text] [Related]
9. Endocervical neoplasia: Pathologic updates in diagnosis and prognosis.
Rivera-Colón G; Zheng W
Semin Diagn Pathol; 2022 May; 39(3):213-227. PubMed ID: 34953647
[TBL] [Abstract] [Full Text] [Related]
10. Identification of clinical trait-related small RNA biomarkers with weighted gene co-expression network analysis for personalized medicine in endocervical adenocarcinoma.
Shi Z; Qu X; Guo C; Zhang L; Peng C; Xie Z; Hua K; Qiu J
Aging (Albany NY); 2021 Sep; 13(18):22361-22374. PubMed ID: 34542422
[TBL] [Abstract] [Full Text] [Related]
11. Construction and validation of nomograms for predicting the prognosis of grade 3 endometrial endometrioid adenocarcinoma cancers: a SEER-based study.
Liu X; Zhao J; Sun Z; Wang G
Bioengineered; 2021 Dec; 12(1):1752-1765. PubMed ID: 33975518
[TBL] [Abstract] [Full Text] [Related]
12. Clinicopathologic characteristics and prognosis comparison of the uterine high grade endometrial carcinomas.
Sucu M; Kucukgoz Gulec U; Paydas S; Guzel AB; Kilic Bagir E; Vardar MA
Ginekol Pol; 2021; 92(4):278-283. PubMed ID: 33751504
[TBL] [Abstract] [Full Text] [Related]
13. Challenges and controversies in the conservative management of uterine and ovarian cancer.
Janda M; McGrath S; Obermair A
Best Pract Res Clin Obstet Gynaecol; 2019 Feb; 55():93-108. PubMed ID: 30243603
[TBL] [Abstract] [Full Text] [Related]
14. Study of the revisited, revised, and expanded Silva pattern system for Chinese endocervical adenocarcinoma patients.
Wang W; Song G; Lin J; Zheng X; Wang Y; Liu Y; Liu C
Hum Pathol; 2019 Feb; 84():35-43. PubMed ID: 30218754
[TBL] [Abstract] [Full Text] [Related]
15. miR-202 Suppresses Cell Proliferation by Targeting FOXR2 in Endometrial Adenocarcinoma.
Deng X; Hou C; Liang Z; Wang H; Zhu L; Xu H
Dis Markers; 2017; 2017():2827435. PubMed ID: 28827892
[TBL] [Abstract] [Full Text] [Related]
16. Folate Receptor Alpha Expression in Platinum Resistant/Refractory Ovarian Carcinomas and Primary Endocervical Adenocarcinomas.
Rubinsak LA; Cohen C; Khanna N; Horowitz IR; Hanley KZ
Appl Immunohistochem Mol Morphol; 2018 Sep; 26(8):567-572. PubMed ID: 27941566
[TBL] [Abstract] [Full Text] [Related]
17. Survival Differences Among uterine Papillary Serous, Clear Cell and Grade 3 Endometrioid Adenocarcinoma Endometrial cancers: A National cancer Database Analysis.
McGunigal M; Liu J; Kalir T; Chadha M; Gupta V
Int J Gynecol Cancer; 2017 Jan; 27(1):85-92. PubMed ID: 27759595
[TBL] [Abstract] [Full Text] [Related]
18. Association of the immunohistochemical detection of gamma-glutamyl transferase expression with clinicopathological findings in postmenopausal women with endometrioid adenocarcinoma of the uterus.
Pitynski K; Ozimek T; Galuszka N; Banas T; Milian-Ciesielska K; Pietrus M; Okon K; Mikos M; Juszczyk G; Sinczak-Kuta A; Stoj A
J Physiol Pharmacol; 2016 Jun; 67(3):395-402. PubMed ID: 27512000
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic value of Musashi-1 in endometrioid adenocarcinoma.
Ma L; Xu YL; Ding WJ; Shao HF; Teng YC
Int J Clin Exp Pathol; 2015; 8(5):4564-72. PubMed ID: 26191146
[TBL] [Abstract] [Full Text] [Related]
20. Trefoil factor family 3 (TFF3) expression and its interaction with estrogen receptor (ER) in endometrial adenocarcinoma.
Mhawech-Fauceglia P; Wang D; Samrao D; Liu S; DuPont NC; Pejovic T
Gynecol Oncol; 2013 Jul; 130(1):174-80. PubMed ID: 23578537
[TBL] [Abstract] [Full Text] [Related]
[Next]
